



CFP-RD2026  
Call for Proposals - Rare Diseases

## Conditions pre-application for Rare Disease Research

### Background

Stichting Dioraphte is a Dutch private foundation that provides financial support to institutions serving the public interest, both domestically and internationally. More information can be found on our [website](#).

Through its Science and Research portfolio, Dioraphte supports medical scientific research activities in the fields of rare diseases and neglected tropical diseases.

Rare diseases affect a significant portion of the population. However, as each individual disease is rare, there is a lack of funding for research and appropriate treatment. Therefore, Dioraphte allocates €1.7 million biennially to contribute to rare disease research. This is the *fourth call for proposals* focused on rare diseases.

A pre-application of up to **maximum five pages** may be submitted under the following conditions. This page limit excludes required references and biosketches. Only applications using the Dioraphte-provided application form will be considered.

### Conditions

- The selection of pre-applications will follow the NWO-XS peer review system (see the pre-application form for details). Each applicant commits to this review system and its deadlines.
- The principal investigator of a winning proposal in the rare disease round 2026 must personally participate in the advisory/selection committee for the rare disease round 2028.
- The research must focus on diseases classified as rare (prevalence <1:2000). Applications specifically targeting (neuro)muscular disorders and metabolic disorders are excluded from this 2026 round.
- Applicants must be affiliated with a center of expertise that has been officially recognized by the Ministry. Note: Each recognized center (per AIMS ID - [click here](#), - and not per disease) may submit only one application.
- A maximum amount of €425,000 can be requested per application. Overhead costs may not exceed 15% of the total budget.
- There are no restrictions on the types of expenses (equipment, personnel, etc.), provided it is clearly justified how these will benefit the research.
- Applications from (co) applicants with ongoing Dioraphte funding are excluded from this round.
- Applications will be assessed based on the quality and societal impact of the proposal, as well as the quality of the center and research group (publications).
- Applications must be written in English and will only be considered if the Dioraphte application form is used.

# dioraphte

- In addition to the application, biosketches (maximum of five pages per person) of the principal investigators must be submitted. The NIH-style biosketch format can be used (NIH style; [click here](#) for an example). The 'eRA Commons user name' is not required). Alternatively, this year, you may also make use of the evidence-based CV from NWO ([click here](#)) or the ERDERA narrative CV ([click here](#); see page 11/12). Regardless what template is chosen, **a URL linking to all publications of the researcher (e.g., a direct PubMed link or ResearchGate page/ORCID) must be included.**
- Applications must be submitted as a **single PDF file** (including application, references, and biosketch(es)) named as follows: [Last name applicant]\_[Name UMC], e.g., Jansen\_ErasmusMC.PDF.
- This file must be sent via email to: **postbus@dioraphte.nl** with the subject line: **CfP-RD2026 and the applicant's last name.**
- The deadline for pre-applications is **1<sup>st</sup> of May 2025.**
- Applications that do not meet the conditions will be excluded from participation without further notification.
- No correspondence will be conducted regarding the outcome.

## Timeline

<b>1 May 2025</b>	Deadline pre-applications / 1 <sup>st</sup> stage
<b>2 June 2025</b>	Distribution of pre-applications for peer review
<b>1 August 2025</b>	Deadline peer review process
<b>5 September 2025</b>	Successful applicants and other applicants informed / 2 <sup>nd</sup> stage
<b>17 November 2025</b>	Deadline 2nd stage full applications
<b>15 January 2026</b>	Final recommendation to the Dioraphte board for approval
<b>28 February 2026</b>	Announcement successful applicants CFP-RD2026